path_2995_sm_supportinginformationTS1.xls68KSupporting Information: Table S1. List of IGV validated somatic single nucleotide variants identified in the oligodendroglioma exome discovery set.
path_2995_sm_supportinginformationTS2.xls43KSupporting Information: Table S2. List of PCR primers for focused Sanger sequencing of CIC, IDH1, and IDH2.
path_2995_sm_supportinginformationTS3.xls87KSupporting Information: Table S3. Summary of tumour diagnosis, 1p19q status, IDH1/2 status, and CIC mutational status.
path_2995_sm_supportinginformationFS1.jpg5248KSupporting Information: Figure S1. Next-generation sequencing analysis of loss of heterozygosity status and gene expression of oligodendroglioma.
path_2995_sm_supportinginformationFS2.jpg2257KSupporting Information: Figure S2. Mutational load of oligodendrogliomas in discovery set.
path_2995_sm_supportinginformationFS3.jpg4205KSupporting Information: Figure S3. Long-range PCR of the CIC gene for deep amplicon sequencing.
path_2995_sm_supportinginformationFS4.jpg1548KSupporting Information: Figure S4. Identification of previously unannotated exon 0 in human CIC.
path_2995_sm_supportinginformationFS5.jpg2904KSupporting Information: Figure S5. Analysis of CIC sequence homology across different species.
path_2995_sm_supportinginforLegFig-Tab.doc48KSupporting Information: Legends Figures S1 to S5 and Table S1 to S3.
path_2995_sm_supportinginformaSuppl.doc52KSupporting Information: Supplementary materials and methods.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.